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Summary. Premature ovarian insufficiency (POI) is a clinical syndrome defined as the loss of ovarian activity before 
the age of 40. POI is a life-changing diagnosis, with profound physical and psychological consequences. Spontaneous 
POI affects approximately 1% of women under the age of 40. However, the rising incidence of iatrogenic POI is of 
 increasing concern. POI is a heterogeneous, multifactorial disorder, and in the majority of cases the etiology is unknown. 
The diagnosis of POI is based on the presence of amenorrhea and of an elevated gonadotropin level. Hormone replace-
ment therapy should be used at least until the average age of menopause to alleviate the symptoms of hypoestrogenism 
and to prevent severe long term consequences especially those of cardiovascular diseases and osteoporosis. The treat-
ment of these women should be coordinated by a multidisciplinary team. Women with POI should be informed that there 
is a small chance of spontaneous pregnancy. IVF with donor oocytes represents the highest chance for pregnancy in these 
patients. Further research is needed to identify the population in risk in a timely manner and to find mechanisms that can 
prolong, recover, or preserve ovarian function.
Introduction
Premature ovarian insufficiency (POI) is a clinical 
syndrome defined as the loss of ovarian activity before 
the age of 40, characterized by elevated gonadotropin 
levels, hypoestrogenism and amenorrhea. The syndrome 
was first described in 1942 by Fuller Albright, who used 
the term ‟primary ovarian insufficiency” to suggest that 
the primary defect lying within the ovary (1). There has 
been a long-standing lack of consensus about the 
nomenclature of the syndrome with a variety of other 
terms in use, such as primary ovarian insufficiency, 
premature ovarian failure, premature menopause, 
gonadal dysgenesis, hypergonadotropic hypogonadism 
etc. It was necessary to reach the consensus about the 
use of standard terminology to clarify the information 
given to women, to improve communication between 
professionals, to facilitate data collection and to help 
further research. European Society of Human 
Reproduction and Embryology (ESHRE) guidelines 
propose the term ‟premature ovarian insufficiency” as 
the one to be used in research and in clinical practice 
(2). The use of the term premature refers to the timeline 
rather than the etiology; it defines ovarian insufficiency 
which occurs before the age of 40 caused by any cause. 
The term insufficiency, instead of the term failure, is 
thought to reflect the unpredictable nature of ovarian 
function in the syndrome more accurately, and it does 
not carry the negative connotation of failure. Despite 
our ongoing efforts to improve our understanding of the 
mechanisms involved, POI is still a poorly understood 
entity with a heterogeneous and extremely complex 
etiology. The knowledge of the syndrome and the 
understanding of the various sequels of POI are vital to 
early diagnosis, appropriate counsel and optimal 
treatment of these patients. In addition to causing 
infertility, POI is associated with multiple sequels, such 
as vasomotor symptoms, urogenital symptoms, neuro-
logical dysfunction, cognitive impairment, bone loss 
and increased risk of cardiovascular diseases (3).
Epidemiology
POI is not an uncommon syndrome and it affects 1% 
of women under the age of 40, 0.1% of women under 
the age of 30 and 1 in 3000 adolescents (4). The in-
cidence of spontaneous POI appears to have remained 
stable. However, in the last decades there has been an 
increasing incidence of iatrogenic POI caused by 
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POI is related to familial occurrence in about 15% of 
cases, which suggests a genetic background (7). 
Statistically significant differences in the prevalence 
were observed across different ethnic groups, ranging 
from 0.1% in Japanese to 1% in Caucasian and 1.4% in 
African American and Hispanic group (8).
Etiology
POI is a heterogeneous, multifactorial disorder and 
its etiology remains poorly understood. In the majority 
of cases, POI etiology is unknown and it is termed as 
idiopathic POI. The pathogenesis of idiopathic POI 
can be explained by three mechanisms: congenital 
reduction in the number of primordial follicles, follicle 
dysfunction, or accelerated follicular apoptosis. POI 
can be caused by chromosomal or genetic defects. 
Abnormalities in the X chromosome have been 
estimated to occur in 12–14% of women with POI, and 
in about 50% of patients with primary amenorrhoea 
(9–11). Chromosomal analysis should be performed in 
all women with non-iatrogenic idiopathic POI. The 
most frequently identified single gene mutation 
associated with POI is the fragile X mental retardation 
1 (FMR1) gene premutation. The full mutation (more 
than 200 CGG trinucleotide repeats) results in in-
tellectual and developmental disability in men who 
carry the mutation. Approximately 23% of women with 
premutation (55–200 CGG repeats) will develop POI 
(12). Women with full mutation or with an intermediate 
sized CGG repeats are not in risk of developing POI. 
Based on its prevalence and severe clinical implications 
for women and their families, fragile -X testing is 
recommended in all women with non-iatrogenic POI (2, 
13). Numerous autosomal genetic mutations have been 
associated with POI. The primary mutation genes are 
those involved in folliculogenesis, genes of sex hormone 
receptors or genes involved in ovarian steroidogenesis 
(14, 15). Routine screening for autosomal gene mutation 
in women with POI is not recommended. Autoimmune 
etiology has been found in about 30% of POI cases and 
it may present itself separately or with some autoimmune 
diseases like adrenal insufficiency, Hashimotoʼs and 
diabetes mellitus type 1. POI of adrenal autoimmune 
origin is the most frequent type in patients with 
autoimmune POI (16, 17). Screening for 21-hydroxylase 
auto antibodies should be performed in women with 
POI of an unknown cause. POI is also associated with 
thyroid autoimmunity and screening for thyroid 
peroxidase autoantibodies should be performed. Some 
associations have been reported between POI and 
infections, such as parotitis virus, human immuno-
deficiency virus, tuberculosis, varicella virus, cytome-
galovirus, shigella and malaria (18). However, their 
contribution to pathogenesis remains unclear. Some 
recent meta-analyses warn of the potential impact of 
environmental pollutants and toxins in the pathogenesis 
of POI but there is no clear evidence of the impact of 
environmental factors on POI (19). Cigarette smoking 
is toxic for ovarian function and there is a connection 
between smoking and earlier menopause, but it is not a 
direct cause of POI (20). POI may also occur after 
iatrogenic procedures like surgical interventions 
(bilateral ovarian cystectomies), chemo or radiotherapy 
treatment or pelvic vessel embolization and it is termed 
as iatrogenic POI (21, 22).
Clinical presentation and diagnosis
The spectrum of the symptomatology of POI is highly 
variable. Women usually present with menstrual irre-
gularity or amenorrhea, with or without symptoms of 
estrogen deficiency. They may present with primary 
(10% of cases of POI) or secondary amenorrhea 
depending on the etiology of POI (23). Women with 
primary amenorrhea may never experience menopausal 
symptoms. Hot flushes, night sweats, dyspareunia, 
vaginal dryness, sleep disturbance, mood changes, dry 
eyes, low libido and the lack of energy are typical of 
POI with secondary amenorrhea and may be the reason 
for an initial medical consultation (24). For some 
women, POI may be diagnosed only during an 
evaluation of infertility.
There are no ideal markers for the diagnosis of POI. 
At first, it is necessary to exclude pregnancy, in any 
reproductive-age women, with secondary amenorrhea. 
The criteria for POI diagnosis are the occurrence of 
amenorrhea for at least four months and increased FSH 
levels ˃ 25 IU/l on two occasions repeated at a four-
week interval (2). The FSH serum level is the gold 
standard test in POI diagnosis. Anti-Mullerian hormone 
(AMH), as a biomarker of the ovarian reserve, could be 
very low not only in POI patients, but also in women 
with regular menstrual cycles with a diminished ovarian 
reserve (DOR) and it should not be routinely used to 
diagnose POI syndrome (25).
Fertility
Infertility issues are the most dramatic problem for 
POI women, with an extremely negative impact on 
the psychological status and the quality of life. Women 
with POI have up to 5% chance of spontaneous 
conceiving after confirming the diagnosis (26). In-
termittent ovarian activity may occur in women with 
POI, although this is likely to decrease with the 
increasing duration of amenorrhea. Artificial repro-
duction techniques are unsuccessful in women with POI 
due to their exhausted pool of oocytes. A range of 
treatments including exogenous estrogen administration, 
corticosteroids, combined oral contraceptives, dehydro-
epiandrosterone have been explored as potential 
treatments for increasing ovarian activity but without 
any significant results on ovulation rate or the possibility 
of conception (27, 28). At present, the oocyte donation 
remains the only proven method and the treatment of 
choice for infertility in women with POI. (2). However, 
oocyte donation pregnancies are associated with a 
higher risk of obstetric complications. Nowadays, new 
methods of infertility treatment in POI patients are 
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being developed. This new treatment was named as in 
vitro activation (IVA) of dominant follicles (29). IVA 
implements chemical stimulation of the ovarian tissue 
with phosphatidylinositol-3-kinase stimulator to acti-
vate primordial, secondary and preantral follicles. A 
cycle of IVA includes laparoscopic surgery in order to 
remove the ovary, cutting the ovary into cortical strips 
and vitrifying. After thawing, the ovarian strips are 
incubated with stimulators and then autografted under 
laparoscopic surgery. After that, patients start ovarian 
stimulation protocol and IVF procedures. There have 
been two healthy delivered babies and two additional 
pregnancies after IVA procedures. Moreover, Stimpfel 
et al. differentiated in vitro stem cells from an adult 
human ovarian cortex. Stem cells have self-renewal and 
regeneration potential and this may open a new 
opportunity in the treatment of premature ovarian 
insufficiency (30, 31).
Management
POI is a serious condition, and patients with POI 
diagnosis are a high risk group, which is due to the lack 
of the ovarian hormone, primarily estrogen, exposed to 
an increased risk of cardiovascular diseases, osteo-
porosis, neurological diseases, genitourinary disorders, 
psychological dysfunction etc. In consequence, these 
patients have a higher morbidity and greater mortality 
than their healthy peers. It is for this reason that all the 
leading gynecological societies recommend hormonal 
replacement therapy (HNL), in the case of POI patients, 
with the purpose of helping induce secondary sexual 
characteristics in adolescents and of preventing a series 
of serious illnesses that may result from a deficiency of 
estrogen in adults (2, 32, 33) HNL is the first choice in 
treating these patients, and the treatment should be 
continued until the age of the expected natural me-
nopause. COC pill containing ethinyl-estradiol could 
also be a suitable option for POI patients who need 
contraception, but HRT is more beneficial to improving 
bone health and cardiovascular markers (34, 35). HNL, 
along with other supportive measures, such as general 
lifestyle and dietary measures with increased calcium 
and vitamin D intake, smoking cessation and alcohol 
intake cessation can significantly improve the quality of 
life of POI patients.
Vasomotor symptoms are the main reason for taking 
HNL in women with POI. Numerous studies of women 
with POI, especially with the iatrogenic form, indicate a 
rapid improvement in vasomotor problems after the 
introduction of HNL (36). Estrogen has an important 
role in regulating and maintaining bone structure, and 
estrogen deficiency, associated with POI. has been 
shown to result in a reduction in bone density and in an 
increased risk of fractures. Estrogens activate osteoblasts 
and have an inhibitory effect on osteoclast activity. 
Furthermore, they favorably affect the cortical and 
trabecular bone. The presence of osteoporosis among 
POI patients is as high as 8–14%, and the use of HNL 
suggests an improvement in the bone density of the 
patients (37).
Reduced life expectancy, due to cardiovascular 
diseases, is observed among women with untreated POI, 
and despite the lack of longitudinal outcome data, HRT is 
strongly recommended to prevent cardiovascular 
morbidity and mortality risk in this population. The risk 
of mortality from ischemic heart disease is said to be 
approximately 80% increased among women with POI, 
in comparison to women with natural menopause (38). 
Vaginal dryness, dyspareunia and incontinence are 
directly associated with the lack of estrogen. Therefore, 
systemic or local therapy is advised in the prevention and 
treatment of genitourinary problems in POI patients (39).
POI is associated with a higher risk of neurological 
dysfunction, cognitive impairment, and dementia, es-
pecially iatrogenic POI (40). There is no clear evidence, 
from prospective controlled studies, that the use of HNL 
reduces the risk of cognitive decline or dementia in 
women with POI.
It is known that the risk of breast cancer increases 
with the later age of menopause it is thus assumed that 
the risk is lower in patients with POI. This was confirmed 
by the research by Wu et al. they showed that the 
incidence of breast cancer is significantly lower in a 
patient with POI in comparison to women with natural 
menopause (41). There is no evidence that HRT in-
creases the risk of breast cancer before the age of natural 
menopause (42). Recent studies also suggest the 
association of various types of progesterone with breast 
cancer, and, with limited evidence, they support the use 
of micronized progesterone (43).
There is an irresistible association between prolonged 
estrogen-only HRT and endometrial cancer, so any in 
all POI patients with uterus only combined estrogen-
progesterone therapy should be used (44). In older 
postmenopausal women, a higher incidence of venous 
thromboembolism with HNL was demonstrated, but 
there is no evidence of a greater incidence of the same 
in women with POI (45). Only a smaller branch of the 
WHI (Women’s Health Initiative) study showed an 
increased risk of developing VTE in POI patients taking 
HNL (46). Transdermal route should be considered in 
women with POI who are at the increased risk of venous 
thromboembolism.
There are many routes of administration, doses, and 
various types of estrogen and progesterone preparations 
that can be used for POI treatment. There are three types 
of estrogens for HNL: 17β-estradiol, ethinyl-estradiol 
and estradiol valerate. There are no studies comparing 
the use of a particular type of estrogen preparation in a 
POI patient. There is very little evidence of the benefits 
of a particular preparation but in the opinion of experts, 
it is recommended to use 17β- estradiol which has more 
physiological effects (47). Estrogens can be admi-
nistrated systemically, in oral or transdermal form, or 
locally. Transdermal route of administration deliver 
hormone directly into the circulation, which avoids 
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complications associated with first pass effect on the 
liver when estrogen is given orally. Avoiding the first 
passage through the liver, it achieves higher plasma 
concentrations with a lower treatment dose and shows 
significantly less negative effects (inflammatory factors, 
blood pressure, lipid profile, and renin) than oral 
administration (48). However, data for women with POI 
does not exist, so we also take the decision of the 
application regime upon their wishes. In women with 
POI who have uterus, it is necessary to add progesterone 
to prevent endometrial cancer. Progesterone can be 
administrated orally, vaginally or in the form of 
intrauterine device system. Again, there are no studies 
on the type of progesterone preparation. However, due 
to fewer side effects on cardiovascular health and due to 
lower risk of endometrium cancer, the recommendation 
is to use natural micronized progesterone instead of 
synthetic progesterone (49). The cyclic mode of 
application of HNL has been shown to reduce the 
occurrence of endometriosis of the ovary and is a highly 
preferable regimen for the patients planning pregnancy 
by oocyte donation. In regard to progesterone, there is 
currently no evidence that a vaginal progesterone gel or 
a transdermal application of progesterone is sufficient 
to protect the endometrium from cancer. Therefore, oral 
administration is still recommended.
When using estrogen in POI patients, a dose is 
required to remove existing symptoms, preventing 
long-term risks to those who are exposed to estrogen 
deficiency while at the same time carrying the least risk 
since they will be taking them for years. An estrogen 
dose that will maintain a serum value of about 50–100 
pg/ml, as found in healthy women, is achieved with 100 
μg of estradiol transdermally (50). Similar concentra-
tions are achieved by oral administration of 2 mg of 
estradiol but they result in supraphysiological con-
centrations of estrons whose clinical significance is 
unknown. There are no studies that prescribe the 
progesterone doses needed to protect the endometrium 
in these patients. It is recommended to apply oral for 
oral administration of 1mg norethisterone per day or 
2.5mg medroxyprogesterone with continuous regimen 
or 10–12 days per month 10 mg medroxyprogesterone 
or 200 mg oral micronized progesterone (2, 44). The 
exact duration of the cycle and the use of progesterone 
may be individualized but it is certain that the period 
between the progesterone administrations should not be 
longer than 12 weeks.
There is no evidence of the ideal duration of HNL in 
these patients, but the recommendation is to apply it 
until the average age of menopause. There is also no 
specific strategy for monitoring these patients. The 
recommendation is to examine the patients once a year 
mostly for the purpose of checking the patients’ 
satisfaction with the therapy and recording any possible 
side effects. The compliance among POI patients is 
very low, so their preferences in terms of route, drug 
and type of hormonal therapy should be respected in 
order to ensure greater compliance.
Conclusion
The diagnosis of premature ovarian insufficiency is 
extremely disturbing for women, especially if they have 
failed to reproduce. Women with POI have complex 
physical and psychological needs, and a multidiscipli-
nary approach is recommended as standard practice to 
improve the quality of life after the loss of ovarian 
function. The early diagnosis and the treatment of these 
patients improve the quality and prolong life expectancy, 
and they are thus an unquestionable population for the 
application of HNL. Further research should focus on a 
better understanding of the disease, by exploring the 
possibility of early detection of the patients in risk and 
the possible prevention of the disease emergence in a 
timely and targeted treatment for the purpose of com-
pletely preventing or delaying the occurrence of POI.
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PRIJEVREMENA OVARIJSKA INSUFICIJENCIJA
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Indira Kosović1, Jasminka Rešić Karara1
Pregledni članak
Ključne riječi: prijevremena ovarijska insuficijencija, hormonsko nadomjesno liječenje
Sažetak. Prijevremena insuficijencija jajnika (eng. premature ovarian insufficiency – POI) klinički je sindrom definiran 
gubitkom aktivnosti jajnika prije 40. godine života. POI dijagnoza je koja mijenja život, s dubokim fizičkim i psihološkim 
posljedicama. Spontani oblik POI-a zahvaća približno 1% žena mlađih od 40 godina, ali sve je veća zabrinutost zbog 
porasta pojavnosti jatrogenog oblika POI. POI je heterogen, multifaktorski poremećaj i u većini slučajeva etiologija mu 
nije poznata. Dijagnoza POI-a temelji se na prisutnosti amenoreje i povišenoj razini FSH. Liječenje bi trebao koordini-
rati multidisciplinarni tim. Hormonsku nadomjesnu terapiju treba koristiti barem do prosječne dobi menopauze kako bi 
se ublažili simptomi hipoestrogenizma i spriječile neželjene dugoročne posljedice, posebno kardiovaskularne bolesti i 
osteoporoza. Žene s POI-em treba obavijestiti da postoji vrlo mala vjerojatnost spontane trudnoće. IVF s donorskim 
oocitima daje najveću šansu za trudnoću ovim pacijenticama. Potrebna su buduća istraživanja kako bi pravovremeno 
prepoznali rizičnu populaciju te pronašli mehanizme koji mogu produljiti, oporaviti ili očuvati funkciju jajnika.
